Gelonghui, December 15, ViaBiotech (01873.HK) announced that on December 15, 2023, the company (together with several subsidiaries), Mr. Mao Chen, and the grantor Raed Capital Holdings 2 Ltd entered into an equity transfer agreement. According to this, the transferee will acquire $1,536,611 of ViaBiotech's registered capital in Shanghai at a cost of $15 million (accounting for about 2.33% of its registered capital).
Via Shanghai is an indirect non-wholly owned subsidiary of the Company. As of the date of this announcement, the Group held 75.79% of Viavia Shanghai's share capital. It is expected that after the equity transfer is completed, the Group's shareholding percentage in Viavia Shanghai will be reduced to 73.46%.
Via Shanghai is a limited liability company established in China. As of the date of this announcement, it is an indirect non-wholly owned subsidiary of the company, mainly engaged in CRO business.
According to the company's CRO business development strategy, dividing the CRO business and CDMO business into two different types of company operations will benefit the two types of business in the development process. When operating different businesses with different capital allocation requirements, each business group will also have greater financial flexibility. This move also enables the management of each business group to follow specific and focused strategies. The qualifying initial public offering is still in the early stages of discussion, and no specific plans have been developed as of the date of this announcement. By introducing investors as shareholders of Via Shanghai, the Group will benefit from investors' industry resources, further enhance its position in the industry, and expand independent financing channels.